Encyclopedia of Cancer

Living Edition
| Editors: Manfred Schwab

Triple-Negative Breast Cancer

  • Benoit Paquette
Living reference work entry
DOI: https://doi.org/10.1007/978-3-642-27841-9_5981-2



Triple-negative breast cancer (TNBC) is a subgroup that accounts for 10–20 % of all breast carcinomas. TNBC is characterized by the absence of three receptors: estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER-2).


Breast cancer is a heterogeneous disease, encompassing a number of distinct biological entities associated with specific morphological and clinical behavior. Technological developments have allowed to sequence the complete genome of breast cancer and compared a large number of tumor samples. From these, studies have emerged five subtypes: luminal A, luminal B, HER2-enriched, basal-like, and claudin-low.

TNBC is sometime referred to as basal-like tumors, as a majority of basal-like cancers are TNBC and approximately 80 % of TNBC are also basal-like breast cancers. TNBC is also associated with younger patients and high-grade...


Breast Cancer Mammary Gland Good Responder TNBC Patient Breast Cancer Radiation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.


  1. Bouchard G, Bouvette G, Therriault H, Bujold R, Saucier C, Paquette B (2013) Pre-irradiation of mouse mammary gland stimulates breast cancer cell migration and development of lung metastases. Br J Cancer 109:1829–1838PubMedCentralCrossRefPubMedGoogle Scholar
  2. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13:4429–4434CrossRefPubMedGoogle Scholar
  3. Holland R, Veling SH, Mravunac M, Hendriks JH (1985) Histologic multifocality of Tis, T1-2 breast carcinomas. Implications for clinical trials of breast-conserving surgery. Cancer 56:979–990CrossRefPubMedGoogle Scholar
  4. Liu NQ, Stingl C, Look MP, Smid M, Braakman RBH, De Marchi T, Sieuwerts AM, Span PN, Sweep FCGJ, Linderholm BK et al (2013) Comparative proteome analysis revealing an 11-protein signature for aggressive triple-negative breast cancer. J Natl Cancer Inst 106:djt376CrossRefGoogle Scholar
  5. Pogoda K, Niwinska A, Murawska M, Pienkowski T (2013) Analysis of pattern, time and risk factors influencing recurrence in triple-negative breast cancer patients. Med Oncol 30:388PubMedCentralCrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  1. 1.Department of Nuclear Medicine and Radiobiology, Faculty of Medicine and Health SciencesUniversité de SherbrookeSherbrookeCanada